Multidisciplinary Care for Patients with Breast Cancer

Surgical Clinics of North America

Volumn 89, Issue 1, 2009, Pages 133-176

  Hulvat, Melissa C ^a,b   Hansen, Nora M ^a,b   Jeruss, Jacqueline S ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Lynn Sage Comprehensive Breast Center   (United States)

Author keywords

Breast cancer; Breast cancer surgery; Breast imaging; Chemotherapy; Neoadjuvant therapy; Radiation therapy; Staging

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FULVESTRANT; GELDANAMYCIN; GEMCITABINE; LAPATINIB; LETROZOLE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PAMIDRONIC ACID; PERTUZUMAB; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ABDOMINOPLASTY; ADJUVANT CHEMOTHERAPY; ARTHRALGIA; AXILLARY LYMPH NODE; BLEEDING; BRACHYTHERAPY; BREAST CANCER; BREAST ENDOPROSTHESIS; BREAST EXAMINATION; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGESTIVE HEART FAILURE; DECISION SUPPORT SYSTEM; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOMAMMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE FERTILITY; FRACTURE; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; IMMUNOTHERAPY; INTESTINE PERFORATION; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARTIAL MASTECTOMY; PATIENT ASSESSMENT; PATIENT CARE; PATIENT SATISFACTION; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; SURGICAL TECHNIQUE; THERAPY EFFECT; THROMBOSIS; TRANSVERSE RECTUS ABDOMINIS MUSCULOCUTANEOUS FLAP; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FERTILITY; HUMANS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT CARE TEAM; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECONSTRUCTIVE SURGICAL PROCEDURES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SENTINEL LYMPH NODE BIOPSY; TAMOXIFEN;

EID: 58849146271     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.10.002     Document Type: Review

References (236)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. National Cancer Institute Web site. Available at:. http://www.cancer.gov Accessed July 1, 2008
3. National Institutes of Health Web site. Available at:. http://www.nih.gov Accessed July 1, 2008
4. National Cancer Institute Breast Cancer Risk Assessment. Available at: http://www.cancer.gov/bcrisktool. Accessed July 1, 2008.
5. Humphrey L.L., Helfand M., Chan B.K., et al. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 137 5 Pt 1 (2002) 347-360
6. Pisano E.D., Gatsonis C., Hendrick E., et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353 17 (2005) 1773-1783
7. Pisano E.D., Hendrick R.E., Yaffe M.J., et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 246 2 (2008) 376-383
8. American Cancer Society. Breast cancer facts & figures 2007-2008 (2007), American Cancer Society, Inc., Atlanta (GA)
9. Yang W., and Dempsey P.J. Diagnostic breast ultrasound: current status and future directions. Radiol Clin North Am 45 5 (2007) 845-861
10. Blair S., McElroy M., Middleton M.S., et al. The efficacy of breast MRI in predicting breast conservation therapy. J Surg Oncol 94 3 (2006) 220-225
11. van den Bosch M.A., Daniel B.L., Mariano M.N., et al. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Invest Radiol 40 7 (2005) 436-441
12. Kuhl C.K. MRI of breast tumors. Eur Radiol 10 1 (2000) 46-58
13. Kuhl C., Kuhn W., Braun M., et al. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back?. Breast 16 Suppl 2 (2007) S34-S44
14. Fischer U., Zachariae O., Baum F., et al. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 14 10 (2004) 1725-1731
15. Lehman C.D., Gatsonis C., Kuhl C.K., et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356 13 (2007) 1295-1303
16. Fletcher S.W., Black W., Harris R., et al. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst 85 20 (1993) 1644-1656
17. Boetes C., Veltman J., van Die L., et al. The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat 86 1 (2004) 31-37
18. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 5 (2004) 427-437
19. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 9473 (2005) 1769-1778
20. Plevritis S.K., Kurian A.W., Sigal B.M., et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295 20 (2006) 2374-2384
21. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 2 (2007) 75-89
22. Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 14 1 (2007) 3-13
23. Samson D.J., Flamm C.R., Pisano E.D., et al. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy?. Acad Radiol 9 7 (2002) 773-783
24. Eubank W.B., and Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 2 (2005) 84-99
25. Kumar R., Chauhan A., Zhuang H., et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98 3 (2006) 267-274
26. Rosen E.L., Eubank W.B., and Mankoff D.A. FDG PET, PET/CT, and breast cancer imaging. Radiographics 27 Suppl 1 (2007) S215-S229
27. Tafra L., Cheng Z., Uddo J., et al. Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 190 4 (2005) 628-632
28. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 22 2 (2004) 277-285
29. Chung A., Liou D., Karlan S., et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg 141 8 (2006) 783-788 [discussion: 8-9]
30. Byrne A.M., Hill A.D., Skehan S.J., et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg 91 11 (2004) 1398-1409
31. Tatsumi M., Cohade C., Mourtzikos K.A., et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33 3 (2006) 254-262
32. Eubank W.B., and Mankoff D.A. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med 34 3 (2004) 224-240
33. Radan L., Ben-Haim S., Bar-Shalom R., et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107 11 (2006) 2545-2551
34. Berriolo-Riedinger A., Touzery C., Riedinger J.M., et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34 12 (2007) 1915-1924
35. Poggi M.M., Danforth D.N., Sciuto L.C., et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98 4 (2003) 697-702
36. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 16 (2002) 1233-1241
37. Singletary S.E. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 184 5 (2002) 383-393
38. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 9503 (2005) 2087-2106
39. Wapnir I.L., Anderson S.J., Mamounas E.P., et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24 13 (2006) 2028-2037
40. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 8 (2002) 567-575
41. Singletary S.E., and Robb G.L. Oncologic safety of skin-sparing mastectomy. Ann Surg Oncol 10 2 (2003) 95-97
42. Chagpar A.B. Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative, and postoperative considerations. Am Surg 70 5 (2004) 425-432
43. Fisher E.R., Gregorio R.M., Fisher B., et al. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36 1 (1975) 1-85
44. Wertheim U., and Ozzello L. Neoplastic involvement of nipple and skin flap in carcinoma of the breast. Am J Surg Pathol 4 6 (1980) 543-549
45. Ho C.M., Mak C.K., Lau Y., et al. Skin involvement in invasive breast carcinoma: safety of skin-sparing mastectomy. Ann Surg Oncol 10 2 (2003) 102-107
46. Carlson G.W., Bostwick III J., Styblo T.M., et al. Skin-sparing mastectomy: oncologic and reconstructive considerations. Ann Surg 225 5 (1997) 570-575 [discussion: 5-8]
47. Kroll S.S., Khoo A., Singletary S.E., et al. Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg 104 2 (1999) 421-425
48. Newman L.A., Kuerer H.M., Hunt K.K., et al. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 5 7 (1998) 620-626
49. Kroll S.S., Schusterman M.A., Tadjalli H.E., et al. Risk of recurrence after treatment of early breast cancer with skin-sparing mastectomy. Ann Surg Oncol 4 3 (1997) 193-197
50. Rivadeneira D.E., Simmons R.M., Fish S.K., et al. Skin-sparing mastectomy with immediate breast reconstruction: a critical analysis of local recurrence. Cancer J 6 5 (2000) 331-335
51. Simmons R.M., Fish S.K., Gayle L., et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol 6 7 (1999) 676-681
52. Carlson G.W., Styblo T.M., Lyles R.H., et al. Local recurrence after skin-sparing mastectomy: tumor biology or surgical conservatism?. Ann Surg Oncol 10 2 (2003) 108-112
53. Cunnick G.H., and Mokbel K. Skin-sparing mastectomy. Am J Surg 188 1 (2004) 78-84
54. Garcia-Etienne C.A., and Borgen P.I. Update on the indications for nipple-sparing mastectomy. J Support Oncol 4 5 (2006) 225-230
55. Laronga C., Kemp B., Johnston D., et al. The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin-sparing mastectomy. Ann Surg Oncol 6 6 (1999) 609-613
56. Opatt D., and Morrow M. The dual role of nipple preservation. J Support Oncol 4 5 (2006) 233-234
57. Petit J.Y., Veronesi U., Orecchia R., et al. Nipple-sparing mastectomy in association with intraoperative radiotherapy (ELIOT): a new type of mastectomy for breast cancer treatment. Breast Cancer Res Treat 96 1 (2006) 47-51
58. Crowe Jr. J.P., Kim J.A., Yetman R., et al. Nipple-sparing mastectomy: technique and results of 54 procedures. Arch Surg 139 2 (2004) 148-150
59. Gerber B., Krause A., Reimer T., et al. Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 238 1 (2003) 120-127
60. Simmons R.M., Brennan M., Christos P., et al. Analysis of nipple/areolar involvement with mastectomy: can the areola be preserved?. Ann Surg Oncol 9 2 (2002) 165-168
61. Stolier A.J., and Grube B.J. Areola-sparing mastectomy: defining the risks. J Am Coll Surg 201 1 (2005) 118-124
62. Simmons R.M., Hollenbeck S.T., and Latrenta G.S. Two-year follow-up of areola-sparing mastectomy with immediate reconstruction. Am J Surg 188 4 (2004) 403-406
63. Zakaria S., and Degnim A.C. Prophylactic mastectomy. Surg Clin North Am 87 2 (2007) 317-331
64. National Cancer Institute statistics. Available at: http://www.cancer.gov/cancertopics/type/breast. Accessed July 1, 2008.
65. Harris R.E., Lynch H.T., and Guirgis H.A. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 60 5 (1978) 955-960
66. Rosen P.P., Groshen S., and Kinne D.W. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 9 9 (1991) 1650-1661
67. Rosen P.P., Groshen S., Kinne D.W., et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 106 5 (1989) 904-910
68. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 6 (2004) 1055-1062
69. Grann V.R., Jacobson J.S., Thomason D., et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20 10 (2002) 2520-2529
70. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22 12 (2004) 2328-2335
71. van Sprundel T.C., Schmidt M.K., Rookus M.A., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93 3 (2005) 287-292
72. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 28 (2006) 4642-4660
73. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 9245 (2000) 1876-1881
74. Consensus statement on guidelines for performing sentinel lymph node dissection in breast cancer. 2005. Available at:. http://www.breastsurgeons.org/slnd.shtml Accessed July 1, 2008
75. Schijven M.P., Vingerhoets A.J., Rutten H.J., et al. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29 4 (2003) 341-350
76. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 30 (2005) 7703-7720
77. Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8 10 (2007) 881-888
78. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 20 17 (2002) 3628-3636
79. Singletary S.E., and Greene F.L. Revision of breast cancer staging: the 6th edition of the TNM classification. Semin Surg Oncol 21 1 (2003) 53-59
80. Brogi E., Torres-Matundan E., Tan L.K., et al. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol 12 2 (2005) 173-180
81. Cserni G., Gregori D., Merletti F., et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 91 10 (2004) 1245-1252
82. van Rijk M.C., Peterse J.L., Nieweg O.E., et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 107 3 (2006) 467-471
83. Rutgers E.J. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol 26 5 (2008) 698-702
84. Schwartz G.F., Giuliano A.E., and Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 94 10 (2002) 2542-2551
85. Hansen N.M., Grube B.J., Ye C., et al. The impact of micrometastases in the sentinel nodes of patients with invasive breast cancer. Breast Cancer Res Treat 106 Suppl 1 (2007) S15
86. Chen S.L., Hoehne F.M., and Giuliano A.E. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 14 12 (2007) 3378-3384
87. Grube B.J., and Giuliano A.E. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 20 3 (2001) 230-237
88. Fant J.S., Grant M.D., Knox S.M., et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 10 2 (2003) 126-130
89. Hwang R.F., Gonzalez-Angulo A.M., Yi M., et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110 4 (2007) 723-730
90. Jeruss J.S., Winchester D.J., Sener S.F., et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 12 1 (2005) 34-40
91. Naik A.M., Fey J., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 240 3 (2004) 462-468 [discussion: 8-71]
92. Van Zee/Memorial Sloan-Kettering Breast Cancer Nomogram. 2008. Available at:. http://www.mskcc.org/mskcc/html/15938.cfm Accessed July 1, 2008
93. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10 10 (2003) 1140-1151
94. Soran A., Evrensel T., Ahrendt G., et al. Use of the breast cancer nomogram to predict non-sentinel nodal positivity in patients having received pre-operative chemotherapy. Ann Surg Oncol 14 1 (2007) 165
95. Xing Y., Foy M., Cox D.D., et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93 5 (2006) 539-546
96. Jeruss J.S., Newman L.A., Ayers G.D., et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer 112 12 (2008) 2646-2654
97. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th edition (2002), Springer, New York 221
98. Benson J.R., and Querci della Rovere G. Management of the axilla in women with breast cancer. Breast 16 2 (2007) 130-136
99. Sosa J.A., Diener-West M., Gusev Y., et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 5 2 (1998) 140-149
100. Orr R.K. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol 6 1 (1999) 109-116
101. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 66 1 (1997) 7-10
102. Khan S.A. Does resection of an intact breast primary improve survival in metastatic breast cancer?. Oncology (Williston Park) 21 8 (2007) 924-931 [discussion: 31-2, 34, 42, passim]
103. Babiera G.V., Rao R., Feng L., et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13 6 (2006) 776-782
104. Blanchard D.K., Shetty P.B., Hilsenbeck S.G., et al. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 247 5 (2008) 732-738
105. Gnerlich J., Jeffe D.B., Deshpande A.D., et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 14 8 (2007) 2187-2194
106. Newman L.A., and Mamounas E.P. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg Clin North Am 87 2 (2007) 279-305
107. Fisher B., Bryant J., Dignam J.J., et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20 20 (2002) 4141-4149
108. Goyal S., Kearney T., and Haffty B.G. Current application and research directions for partial-breast irradiation. Oncology (Williston Park) 21 4 (2007) 449-461 [discussion: 61-2, 64, 70]
109. Hughes K.S., Schnaper L.A., Berry D., et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351 10 (2004) 971-977
110. Smith B.D., Gross C.P., Smith G.L., et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 98 10 (2006) 681-690
111. Arthur D.W., Koo D., Zwicker R.D., et al. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys 56 3 (2003) 681-689
112. Morrow M., Strom E.A., Bassett L.W., et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52 5 (2002) 256-276
113. Pawlik T.M., Buchholz T.A., and Kuerer H.M. The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer. J Am Coll Surg 199 3 (2004) 479-492
114. Polgar C., Major T., Fodor J., et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 60 4 (2004) 1173-1181
115. Jeruss J.S., Vicini F.A., Beitsch P.D., et al. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol 13 7 (2006) 967-976
116. Sanders M.E., Scroggins T., Ampil F.L., et al. Accelerated partial breast irradiation in early-stage breast cancer. J Clin Oncol 25 8 (2007) 996-1002
117. Taghian A.G., and Recht A. Update on accelerated partial-breast irradiation. Curr Oncol Rep 8 1 (2006) 35-41
118. Patel R.R., and Arthur D.W. The emergence of advanced brachytherapy techniques for common malignancies. Hematol Oncol Clin North Am 20 1 (2006) 97-118
119. Keisch M., Vicini F., Kuske R.R., et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 55 2 (2003) 289-293
120. Pawlik T.M., Perry A., Strom E.A., et al. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer 100 3 (2004) 490-498
121. Keisch M., Vicini F., Scroggins T., et al. Thirty-nine month results with MammoSite brachytherapy applicator: details regarding cosmesis, toxicity and local control in partial breast irradiation. Int J Radiat Oncol Biol Phys 63 2 (2005) S6
122. Veronesi U., Arnone P., Veronesi P., et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer: results on a large series. Ann Oncol 19 9 (2008) 1553-1560
123. Arthur D. Accelerated partial breast irradiation: a change in treatment paradigm for early stage breast cancer. J Surg Oncol 84 4 (2003) 185-191
124. Consensus Statement for Accelerated Partial Breast Irradiation. 2005. Available at:. http://www.breastsurgeons.org/apbi.shtml Accessed July 1, 2008
125. Vicini F., Arthur D., Polgar C., et al. Defining the efficacy of accelerated partial breast irradiation: the importance of proper patient selection, optimal quality assurance, and common sense. Int J Radiat Oncol Biol Phys 57 5 (2003) 1210-1213
126. Lee M.C., and Jagsi R. Postmastectomy radiation therapy: indications and controversies. Surg Clin North Am 87 2 (2007) 511-526
127. Early Breast Cancer Trialists' Collaborative Group.Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333 22 (1995) 1444-1455
128. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 5 (2001) 1539-1569
129. Pierce L.J. The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23 8 (2005) 1706-1717
130. Buchholz T.A., Tucker S.L., Masullo L., et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20 1 (2002) 17-23
131. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
132. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel project B-18. J Clin Oncol 15 7 (1997) 2483-2493
133. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 4 (2002) 681-695
134. Buchholz T.A., Lehman C.D., Harris J.R., et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 26 5 (2008) 791-797
135. Carlson RW, Allred C, Andersen BO, et al. Members NBCP. NCCN clinical practice guidelines in oncology: breast cancer. Proceedings of the American Society of Clinical Oncology; 2008.
136. Oncotype DX. Genomic Health, Inc. 2008. Available at:. http://www.genomichealth.com/oncotype/ Accessed July 1, 2008
137. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 4 (2001) 980-991
138. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23 12 (2005) 2716-2725
139. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 9132 (1998) 930-942
140. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
141. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 14 (2006) 1658-1667
142. Dressler L.G., Berry D.A., Broadwater G., et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23 19 (2005) 4287-4297
143. Yamashiro H., and Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 13 1 (2008) 3-7
144. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
145. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23 16 (2005) 3686-3696
146. Nabholtz J., Pienkowski T., mackey J., et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21 (2002) 141 [abstract]
147. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 16 (2008) 1663-1671
148. Bhattacharyya A., Ear U.S., Koller B.H., et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biolumin Chemilumin 275 31 (2000) 23899-23903
149. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 8 (1998) 2672-2685
150. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 6 (2002) 1456-1466
151. Guarneri V., Frassoldati A., Giovannelli S., et al. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. Cancer Lett 248 2 (2007) 175-185
152. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005) 188-194
153. Mieog J.S., van der Hage J.A., and van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94 10 (2007) 1189-1200
154. Jeruss J.S., Mittendorf E.A., Tucker S.L., et al. Staging of breast cancer in the neoadjuvant setting. Cancer Res 68 16 (2008) 6477-6481
155. Jeruss J.S., Mittendorf E.A., Tucker S.L., et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26 2 (2008) 246-252
156. Engel R.H., and Kaklamani V.G. HER2-positive breast cancer: current and future treatment strategies. Drugs 67 9 (2007) 1329-1341
157. Bange J., Zwick E., and Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 7 5 (2001) 548-552
158. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89 10 (1992) 4285-4289
159. Henson E.S., Hu X., and Gibson S.B. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 12 3 Pt 1 (2006) 845-853
160. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
161. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
162. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
163. ®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 (2005) S5
164. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
165. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 31 (2005) 7811-7819
166. Nahta R., and Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8 6 (2006) 215
167. Longo R., Torino F., and Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 13 5 (2007) 497-517
168. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 3 (2006) 1630-1639
169. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24 18S (2006) 503
170. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 26 (2006) 2733-2743
171. Mayer E.L., Lin N.U., and Burstein H.J. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 5 3 (2007) 314-323
172. Roy V., Pockaj B.A., Northfelt D.W., et al. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol 26 15S (2008) 563
173. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 9114 (1998) 1451-1467
174. Mincey B.A., Palmieri F.M., and Perez E.A. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist 7 3 (2002) 246-250
175. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
176. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
177. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
178. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 23 (2006) 2727-2741
179. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
180. Salter J.T., and Miller K.D. Antiangiogenic agents in breast cancer. Cancer Invest 25 7 (2007) 518-526
181. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 1 (1997) 4-25
182. Heer K., Kumar H., Read J.R., et al. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7 11 (2001) 3491-3494
183. Ragaz J., Miller K., Badve S., et al. Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER: results from the British Columbia Tissue Microarray Project. J Clin Oncol 22 14S (2004) 524
184. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 2 (2004) 145-147
185. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 11 (2006) 1779-1802
186. Miller K.D., Wang M., gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperation Oncology Group (E2100). Br Can Res Treat 94 (2005) S6
187. Spalding B.J. Thumbs up for Avastin. Nat Biotechnol 26 4 (2008) 365
188. Hayes D.F., Miller K., and Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 16 Suppl 2 (2007) S17-S19
189. Curigliano G., Rescigno M., and Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. Breast 16 Suppl 2 (2007) S20-S26
190. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
191. Mittendorf E.A., Peoples G.E., and Singletary S.E. Breast cancer vaccines: promise for the future or pipe dream?. Cancer 110 8 (2007) 1677-1686
192. Engelhorn M.E., Guevara-Patino J.A., Merghoub T., et al. Mechanisms of immunization against cancer using chimeric antigens. Mol Ther 16 4 (2008) 773-781
193. Chopra A., Kim T.S., OS I., et al. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int J Cancer 118 11 (2006) 2888-2898
194. Avigan D., Vasir B., Gong J., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10 14 (2004) 4699-4708
195. Bruhn K.W., Craft N., and Miller J.F. Listeria as a vaccine vector. Microbes Infect 9 10 (2007) 1226-1235
196. Collins S.A., Guinn B.A., Harrison P.T., et al. Viral vectors in cancer immunotherapy: which vector for which strategy?. Curr Gene Ther 8 2 (2008) 66-78
197. Freire T., Lo-Man R., Piller F., et al. Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination. Glycobiology 16 5 (2006) 390-401
198. Mittendorf E.A., Holmes J.P., Ponniah S., et al. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 57 10 (2008) 1511-1521
199. Elder E.E., Brandberg Y., Bjorklund T., et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast 14 3 (2005) 201-208
200. Alderman A.K., Hawley S.T., Waljee J., et al. Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer. Cancer 112 3 (2008) 489-494
201. Djohan R., Gage E., and Bernard S. Breast reconstruction options following mastectomy. Cleve Clin J Med 75 Suppl 1 (2008) S17-S23
202. Reavey P., and McCarthy C.M. Update on breast reconstruction in breast cancer. Curr Opin Obstet Gynecol 20 1 (2008) 61-67
203. Zienowicz R.J., and Karacaoglu E. Implant-based breast reconstruction with allograft. Plast Reconstr Surg 120 2 (2007) 373-381
204. Breuing K.H., and Warren S.M. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg 55 3 (2005) 232-239
205. Warren A.G., Morris D.J., Houlihan M.J., et al. Breast reconstruction in a changing breast cancer treatment paradigm. Plast Reconstr Surg 121 4 (2008) 1116-1126
206. FDA breast implants home page. 2006. Available at:. http://www.fda.gov/cdrh/breastimplants Accessed July 1, 2008
207. Hansen N.M., Fen J.W., Fine N.A., et al. Plastic surgery: a component in the comprehensive care of cancer patients. Oncology 16 (2002) 1685-1698
208. Ascherman J.A., Hanasono M.M., Newman M.I., et al. Implant reconstruction in breast cancer patients treated with radiation therapy. Plast Reconstr Surg 117 2 (2006) 359-365
209. Keller A. The deep inferior epigastric perforator free flap for breast reconstruction. Ann Plast Surg 46 5 (2001) 474-479 [discussion: 9-80]
210. Granzow J.W., Levine J.L., Chiu E.S., et al. Breast reconstruction with gluteal artery perforator flaps. J Plast Reconstr Aesthet Surg 59 6 (2006) 614-621
211. Disa J.J., McCarthy C.M., Mehrara B.J., et al. Immediate latissimus dorsi/prosthetic breast reconstruction following salvage mastectomy after failed lumpectomy/irradiation. Plast Reconstr Surg 121 4 (2008) 159e-164e
212. Clough K.B., Cuminet J., Fitoussi A., et al. Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. Ann Plast Surg 41 5 (1998) 471-481
213. Waljee J.F., Hu E.S., Newman L.A., et al. Predictors of breast asymmetry after breast-conserving operation for breast cancer. J Am Coll Surg 206 2 (2008) 274-280
214. Bulstrode N.W., and Shrotria S. Prediction of cosmetic outcome following conservative breast surgery using breast volume measurements. Breast 10 2 (2001) 124-126
215. Audretsch W., Rezai M., Kolotas C., et al. Tumor-specific immediate reconstruction in breast cancer patients. Perspectives in plastic surgery 11 (1998) 71-100
216. Asgeirsson K.S., Rasheed T., McCulley S.J., et al. Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol 31 8 (2005) 817-823
217. Baildam A.D. Oncoplastic surgery for breast cancer. Br J Surg 95 1 (2008) 4-5
218. Rietjens M., Urban C.A., Rey P.C., et al. Long-term oncological results of breast conservative treatment with oncoplastic surgery. Breast 16 4 (2007) 387-395
219. Gradishar W.J., and Hellmund R. A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2 4 (2002) 282-286
220. Arnon J., Meirow D., Lewis-Roness H., et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 7 4 (2001) 394-403
221. Falcone T., Attaran M., Bedaiwy M.A., et al. Ovarian function preservation in the cancer patient. Fertil Steril 81 2 (2004) 243-257
222. Lutchman Singh K., Muttukrishna S., Stein R.C., et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96 12 (2007) 1808-1816
223. Gupta P.B., and Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 102 1-5 (2006) 71-78
224. Lee S.J., Schover L.R., Partridge A.H., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24 18 (2006) 2917-2931
225. Telfer E.E., McLaughlin M., Ding C., et al. A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Humanit Rep 23 5 (2008) 1151-1158
226. Xu M., Kreeger P.K., Shea L.D., et al. Tissue-engineered follicles produce live, fertile offspring. Tissue Eng 12 10 (2006) 2739-2746
227. Badgwell B.D., Povoski S.P., Abdessalam S.F., et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 10 4 (2003) 376-380
228. Blanchard D.K., Donohue J.H., Reynolds C., et al. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 138 5 (2003) 482-487
229. Chung M.A., Steinhoff M.M., Cady B., et al. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 184 4 (2002) 310-314
230. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18 13 (2000) 2553-2559
231. Heuts E.M., van der Ent F.W., Hulsewe K.W., et al. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients. Acta Chir Belg 107 3 (2007) 279-283
232. Palesty J.A., Foster J.M., Hurd T.C., et al. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 93 2 (2006) 129-132
233. Reitsamer R., Peintinger F., Prokop E., et al. Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol 29 3 (2003) 221-223
234. Roumen R.M., Kuijt G.P., Liem I.H., et al. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 88 12 (2001) 1639-1643
235. Schrenk P., Hatzl-Griesenhofer M., Shamiyeh A., et al. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 77 3 (2001) 165-170
236. Smidt M.L., Janssen C.M., Kuster D.M., et al. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12 1 (2005) 29-33